Results from a Phase 2 trial investigating adalimumab for chronic plaque psoriasis were posted on 2026-06-24. The study, which enrolled 18 participants, focused on evaluating skin transcriptional profiles and measured clinical outcomes in 14 participants.
Background
Adalimumab is a biologic medication used in the treatment of various inflammatory conditions, including chronic plaque psoriasis. The trial aimed to follow the modification of skin transcriptomics profiles in psoriatic patients during successful adalimumab biotherapy.
Trial design
This was a Phase 2 trial (NCT01872546) that enrolled 18 adult participants. The study focused on individuals with chronic plaque psoriasis and involved treatment with adalimumab every week. The investigators proposed to compare skin transcriptomics profiles of normal skin, psoriatic non-lesional skin, and psoriatic lesional skin before and after biotherapy.
Key results
The trial reported key measurements for participants receiving adalimumab:
- The Psoriasis Area and Severity Index (PASI) was measured in 14 participants.
- Dermatology Life Quality Index (DLQI) Scores were measured in 14 participants.
What this means
The posting of these results indicates that data collection for key clinical outcomes in this Phase 2 study of adalimumab for chronic plaque psoriasis has been completed. The trial measured the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) Scores in 14 participants. These measurements are standard for assessing disease severity and impact on quality of life in psoriasis studies and are foundational for understanding the drug's potential effects in this patient population.
Source
The trial results were posted on 2026-06-24 on ClinicalTrials.gov, an official database of clinical studies. The full details are available on clinicaltrials.gov under the identifier NCT01872546.